Open AccessIdentification of Novel SARS-CoV-2 Inhibitors: A Structure-Based Virtual Screening Approach
Author(s) -
Abdellah El Aissouq,
Oussama Chedadi,
Mohammed Bouachrıne,
Abdelkrim Ouammou
Publication year - 2021
Publication title -
journal of chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.436
H-Index - 50
eISSN - 2090-9063
pISSN - 2090-9071
DOI - 10.1155/2021/1901484
Subject(s) - drugbank , ritonavir , autodock , virtual screening , chemistry , covid-19 , nelfinavir , coronavirus , atazanavir , pharmacology , virology , computational biology , drug discovery , drug , human immunodeficiency virus (hiv) , viral load , disease , antiretroviral therapy , medicine , in silico , biochemistry , infectious disease (medical specialty) , gene , biology
The recent outbreak of the coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in the last few months raised global health concern. Previous research described that remdesivir and ritonavir can be used as effective drugs against COVID-19. In this study, we applied the structure-based virtual screening (SBVS) on the high similar remdesivir- and ritonavir-approved drugs, selected from the DrugBank database as well as on a series of ritonavir derivatives, selected from the literature. The aim was to provide new potent SARS-CoV-2 main protease (Mpro) inhibitors with high stability. The analysis was performed using AutoDock VINA implicated in the PyRx 0.8 tool. Based on the ligand binding energy, 20 compounds were selected and then analyzed by AutoDock tools. Among the 20 compounds, 3 compounds were selected as high-potent anti-COVID-19.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom